PALEXIA LP (tapentadol), opioid analgesic

Insufficient clinical benefit in the treatment of severe, chronic non-cancer, non-neuropathic pain in adults that can only be adequately treated with opioid analgesics.

• PALEXIA LP has Marketing Authorisation in the treatment of severe, chronic pain in adults that can only be adequately treated with opioid analgesics.
• As a reminder, PALEXIA LP received a favorable opinion for reimbursement in the treatment of chronic severecancer pain.Its clinical benefit is low in this indication.
• In chronic, severe non-cancer, non-neuropathic pain, given the clinically poorly-relevant efficacy demonstrated in studies with many methodological limitations, the potential for abuse and dependence, and the existence of alternatives for pain management, PALEXIA LP has no role in the treatment strategy.